Westhampton Capital LLC bought a new stake in Celgene Co. (NASDAQ:CELG) during the 2nd quarter, Holdings Channel reports. The firm bought 4,990 shares of the biopharmaceutical company’s stock, valued at approximately $461,000.
Several other institutional investors have also recently bought and sold shares of the company. Savant Capital LLC grew its position in shares of Celgene by 6.5% in the second quarter. Savant Capital LLC now owns 2,359 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 145 shares during the last quarter. Enterprise Trust & Investment Co acquired a new stake in Celgene during the second quarter worth approximately $1,816,000. Ruffer LLP grew its position in Celgene by 29.7% during the second quarter. Ruffer LLP now owns 3,116,161 shares of the biopharmaceutical company’s stock worth $288,042,000 after buying an additional 713,687 shares in the last quarter. H D Vest Advisory Services grew its position in Celgene by 2.9% during the second quarter. H D Vest Advisory Services now owns 9,731 shares of the biopharmaceutical company’s stock worth $900,000 after buying an additional 277 shares in the last quarter. Finally, Achmea Investment Management B.V. grew its position in Celgene by 21.4% during the second quarter. Achmea Investment Management B.V. now owns 90,415 shares of the biopharmaceutical company’s stock worth $8,358,000 after buying an additional 15,908 shares in the last quarter. 74.04% of the stock is currently owned by institutional investors.
CELG has been the topic of a number of analyst reports. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target on the stock in a research report on Tuesday, July 23rd. ValuEngine downgraded Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Mizuho downgraded Celgene from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $103.00 to $100.00 in a research report on Monday. Barclays downgraded Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a research report on Friday, May 3rd. Finally, Cowen reissued a “hold” rating and set a $102.00 price target on shares of Celgene in a research report on Tuesday, July 30th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and three have assigned a buy rating to the company. Celgene has a consensus rating of “Hold” and a consensus target price of $94.60.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The company had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same period in the prior year, the company earned $2.16 EPS. Celgene’s revenue was up 15.4% compared to the same quarter last year. Equities analysts anticipate that Celgene Co. will post 9.96 earnings per share for the current fiscal year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What is a Reverse Stock Split?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.